Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
出版年份 2019 全文链接
标题
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
作者
关键词
-
出版物
BIODRUGS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-16
DOI
10.1007/s40259-019-00375-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors
- (2017) Daniel J. Scherer et al. INTERNAL MEDICINE JOURNAL
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
- (2016) Paul M. Ridker et al. AMERICAN HEART JOURNAL
- A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy
- (2016) M Levisetti et al. CTS-Clinical and Translational Science
- Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
- (2016) Emilie M.J. van Brummelen et al. ONCOLOGIST
- What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
- (2016) Evan A. Stein Current Opinion in Endocrinology Diabetes and Obesity
- Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
- (2015) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis
- (2015) Sarah S. Thomas et al. BIODRUGS
- Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality
- (2014) M. Benjamin Hock et al. AAPS Journal
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations
- (2014) G. Shankar et al. AAPS Journal
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Reducing Elevated Plasma LDL Cholesterol: The Central Role of the LDL Receptor
- (2014) J Vincent CLINICAL PHARMACOLOGY & THERAPEUTICS
- Lipid lowering with PCSK9 inhibitors
- (2014) Razvan T. Dadu et al. Nature Reviews Cardiology
- 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 – LBA and immunogenicity)
- (2014) Lauren Stevenson et al. Bioanalysis
- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway
- (2013) A.L. Catapano et al. ATHEROSCLEROSIS
- Evolution and Emergence of Therapeutic Monoclonal Antibodies
- (2013) Ian N. Foltz et al. CIRCULATION
- Immunogenicity testing strategy and bioanalytical assays for antibody–drug conjugates
- (2013) Sarah A Hoofring et al. Bioanalysis
- Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
- (2011) D. Pascual-Salcedo et al. RHEUMATOLOGY
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Development trends for human monoclonal antibody therapeutics
- (2010) Aaron L. Nelson et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
- (2009) Marianne Abifadel et al. HUMAN MUTATION
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- (2009) Josef S Smolen et al. LANCET
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†
- (2008) Daping Fan et al. BIOCHEMISTRY
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
- (2008) Gopi Shankar et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now